All In Biotech

Drug Trial Radar · NCT06716021

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

750

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Milestone Pharmaceuticals Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-national, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of etripamil NS in patients with atrial fibrillation (AF). This study includes Screening Visit, Randomization Visit, a Treatment Period with scheduled Follow-up Visits (Monthly Follow-up and Post-treatment Follow-up Visits), a Final Study Visit, and an End of Study Telephone Follow up Visit. Each patient will be randomized 1:1 to receive placebo or 70 mg Etripamil NS regimens. Patients will self-administer study drug for a perceived episode of AF with RVR with an initial dose of placebo or 70 mg etripamil NS, followed by an optional second dose of the same study drug 10 minutes after the first dose if the patient continues to experience symptoms. Patients may treat up to a maximum of 4 episodes in the study. Informed consent will be obtained prior to any study procedures.

Conditions

  • Atrial Fibrillation

Interventions

  • PlaceboDrug

    The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.

  • EtripamilDrug

    The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate the efficacy of etripamil NS over placebo in patients with AF.Time frame: 30 minutes from first drug administration

Locations

23 sites in 3 countries. Site status is shown where the registry gives one.

  • Blue Coast Research Center, LLC

    Vista, California · Recruiting

  • Interventional Cardiology Medical Group (West Hills, CA)

    West Hills, California · Recruiting

  • South Denver Cardiology Associates P.C

    Littleton, Colorado · Recruiting

  • St Luke's Regional Medical Center, Ltd

    Boise, Idaho · Recruiting

  • TidalHealth Peninsula Regional, Inc

    Salisbury, Maryland · Recruiting

  • Cardiovascular Associates Of The Delaware Valley

    Haddon Heights, New Jersey · Recruiting

  • Weill Cornell Medicine

    Manhattan, New York · Recruiting

  • Cardiology Consultants of Philadelphia (CCP)

    Yardley, Pennsylvania · Recruiting

  • The Jackson Clinic, PA

    Jackson, Tennessee · Recruiting

  • Montreal Heart Institute

    Montreal, Quebec, Canada · Recruiting

  • CardioVasc HR Inc

    Saint-Jean-sur-Richelieu, Quebec, Canada · Recruiting

  • Gelre Ziekenhuizen

    Apeldoorn, Gelderland, Netherlands · Recruiting

  • Rijnstate Ziekenhuis

    Arnhem, Gelderland, Netherlands · Recruiting

  • Gelderse Vallei Ziekenhuis

    Ede, Gelderland, Netherlands · Recruiting

  • Jeroen Bosch Ziekenhuis

    's-Hertogenbosch, North Brabant, Netherlands · Recruiting

  • Amphia Ziekenhuis

    Breda, North Brabant, Netherlands · Recruiting

  • Elkerliek Ziekenhuis

    Helmond, North Brabant, Netherlands · Recruiting

  • Bravis ziekenhuis

    Roosendaal, North Brabant, Netherlands · Recruiting

  • Noordwest Ziekenhuisgroep

    Alkmaar, North Holland, Netherlands · Recruiting

  • ZGT

    Hengelo, Overijssel, Netherlands · Recruiting

  • Frisius Medisch Centrum

    Leeuwarden, Provincie Friesland, Netherlands · Recruiting

  • Van Weel-Bethesda Ziekenhuis

    Dirksland, South Holland, Netherlands · Recruiting

  • Ikazia Ziekenhuis

    Rotterdam, South Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.